Expanding the role of chromosomal microarray analysis in the evaluation of recurrent pregnancy loss
Journal of Reproductive Immunology · 2024-02 · 161 · 104188
DOI: 10.1016/j.jri.2023.104188 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Reproductive Immunology, 2024-02. Verfasst von Jasmine Eliwa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Obstetrics and Gynecology, University of Tennessee Health Sciences Center-Memphis, Memphis, TN, USA. Hauptthemen laut MEDLINE: Abortion, Habitual, Antiphospholipid Syndrome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Multiple factors contribute to recurrent pregnancy loss (RPL). This review highlights the latest international guidelines for RPL workup, including immunological testing, by the American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), and the Royal College of Obstetricians and Gynaecologists (RCOG). These three societies recommend testing for antiphospholipid syndrome. ESHRE and RCOG also recommend thyroid peroxidase antibody testing, whereas ASRM does not. All guidelines advise against testing of natural killer cells, cytokines, antinuclear antibodies, human leukocyte antigen (HLA) compatibility, anti-HLA antibodies, and anti-sperm antibodies. However, when following ASRM, ESHRE or RCOG diagnostic guidelines, over 50% of cases have no identifiable cause. Genetic testing of products of conception (POC) can improve our understanding of unexplained RPL as aneuploidy is a common cause of RPL. Based on studies reporting results from chromosomal microarray analysis (CMA) of POC, we propose a novel algorithm for RPL evaluation. The algorithm involves following evidence-based societal guidelines (published by ASRM, ESHRE, or RCOG), excluding parental karyotyping, in combination with CMA testing of miscarriage tissue. When utilizing this new evaluation algorithm, the number of unexplained cases of RPL decreases from over 50% to less than 10%. As a result, most patients are provided an explanation for their loss and healthcare costs are potentially reduced. Patients with an otherwise negative workup with euploid POC, are classified as "truly unexplained RPL". These patients are excellent candidates for enrollment in randomized, controlled trials examining novel immunological testing and treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Obstetrics and Gynecology, University of Tennessee Health Sciences Center-Memphis, Memphis, TN, USA.
- Infertility Division, Obstetrics & Gynecology Department, St George Hospital - University Medical Center - University of Balamand, Beirut, Lebanon.
- Division of Obstetrics and Gynecology, University of Tennessee Health Sciences Center-Memphis, Memphis, TN, USA; Recurrent Pregnancy Loss Center, Fertility Associates of Memphis, Memphis, TN, USA. Electronic address: wk…
Zitieren
APA
Eliwa, J., Papas, R. S., & Kutteh, W. H. (2024). Expanding the role of chromosomal microarray analysis in the evaluation of recurrent pregnancy loss. Journal of Reproductive Immunology, 161, 104188. https://doi.org/10.1016/j.jri.2023.104188
Vancouver
Eliwa J, Papas RS, Kutteh WH. Expanding the role of chromosomal microarray analysis in the evaluation of recurrent pregnancy loss. Journal of Reproductive Immunology. 2024;161:104188. doi:10.1016/j.jri.2023.104188
BibTeX
@article{Eliwa2024,
author = {Eliwa, Jasmine and Papas, Ralph S and Kutteh, William H},
title = {Expanding the role of chromosomal microarray analysis in the evaluation of recurrent pregnancy loss},
journal = {Journal of Reproductive Immunology},
year = {2024},
volume = {161},
pages = {104188},
doi = {10.1016/j.jri.2023.104188}
}
EUVIMED